Freed AI vs Pfizer
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Francisco AI medical scribe delivering SOAP notes within 2 minutes of a visit; no EHR integration needed, making it immediately accessible to solo clinicians and small practices.
About
Freed AI is a San Francisco-based medical technology startup that provides clinicians with an AI-powered medical scribe accessible via mobile app that records patient visit audio, transcribes the conversation, and generates a complete SOAP note formatted for direct paste into any EHR. Freed differentiates from other ambient scribing tools through its simplicity and accessibility — clinicians start and stop recordings with a tap, and notes are delivered within 2 minutes without requiring EHR integrations or complex IT deployment. The product's one-tap workflow and near-immediate turnaround make it accessible to solo practitioners and small clinics that need ambient scribing without enterprise procurement processes. Freed's AI is designed to capture not just what was said but what was clinically significant, filtering conversation content to produce concise, structured notes rather than verbose transcriptions. The company has grown rapidly through physician word-of-mouth and healthcare professional communities, with thousands of clinicians using the product. Founded in 2022, Freed has gained traction as a lightweight, affordable alternative to enterprise ambient scribing platforms.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.